Semmelweis Egyetem — Clinical Trial Site

15 Registered trials

7 Currently recruiting

Organisation

Semmelweis Egyetem

Location

Budapest, Hungary

Identifier

ORG-100049145

Address

Baross Utca 23, 1082, Hungary

Departments

Belgyogyaszati es Onkologiai Klinika
Belgyógyászati és Onkológiai Klinika Onkológiai Részleg
Belgyógyászati és Onkológiai Központ
Department of Oncology
Onkológiai Profil

Clinical trials at this site (15)

Search interface

A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting

2025-524498-17-00 Pretreated Unresectable Locally Advanced or Metastatic 10 2026-05-08
Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re… Recruiting

2023-504918-29-00 Hormone receptor positive breast cancer 5 2024-08-22
A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan… Recruiting

2025-520566-22-00 Hormone Receptor-Positive, HER2-Negative Advanced/Metas 5 2025-11-10
A clinical study of sacituzumab tirumotecan with or without pembrolizumab in people with breast cancer (MK-2870-011) Recruiting

2024-516834-36-00 Locally recurrent unresectable or metastatic TNBC with 5 2025-07-08
A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto… Recruiting

2023-504180-16-00 Advanced Breast Cancer 5 2025-04-07
Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc… Recruiting

2024-513852-13-00 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic 5 2025-01-20
A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic B… Recruiting

2022-503114-23-00 Breast Cancer 3 2023-12-19
A study to evaluate the safety and the activity of S095029 as a part of combination therapy in advanced gastroesophageal junction/gastric ca… Ended

2023-507995-33-00 MSI-H/dMMR Gastric cancer 9 2024-05-23
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu… Ended

2022-500014-26-00 Locally-Advanced unresectable or Metastatic breast canc 5 2022-06-24
Study of AZD5305 as Monotherapy and with Anti-Cancer Agents in Patients with Advanced Solid Malignancies Ended

2022-502856-29-00 Advanced Solid Tumors 7 2021-07-27
Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive… Ended

2023-505249-24-00 HER2-positive metastatic breast cancer 5 2021-05-27
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced HR Positive and HER2-Negative BC Ended

2023-503903-27-00 metastatic or locally advanced Hormone Receptor positiv 4 2023-10-11
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended

2023-505458-16-00 Gastric and Gastroesophageal Junction Cancer With FGFR2 5 2022-09-13
A Study Evaluating Bemarituzumab in Solid Tumors with FGFR2b Overexpression Ended

2023-505455-44-00 Solid tumours 9 2022-06-29